Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Turmeric and black pepper combo tested to fight inflammation after heart attack

NCT ID NCT07149961

Disease control Sponsor: Universitas Diponegoro Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested whether a supplement combining curcumin (from turmeric) and piperine (from black pepper) can reduce inflammation and oxidative stress in 50 adults who had a heart attack and underwent a procedure to open blocked arteries. Participants took the supplement or a placebo for 28 days. Researchers measured blood markers of inflammation and oxidative stress at the start, shortly after the procedure, and after 28 days to see if the supplement offered extra protection.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
curcumin and piperine (turmeric and black pepper extract)
What this could lead to
If it works, this could point toward a simple, natural supplement to help reduce inflammation and oxidative stress after a heart attack, potentially improving recovery.
What could go wrong
This is a small, completed trial with only 50 participants, so results may not apply widely. The supplement may not show significant benefits over standard care, and high doses could affect liver or kidney function.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

50 people

The number who actually took part.

Started

Feb 2025

Finished

May 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 to 80 years. * Confirmed diagnosis of ST-Elevation Myocardial Infarction (STEMI). Symptom onset within 12 hours, or within 12 to 72 hours in cases with an indication for primary percutaneous coronary intervention (PPCI). * Receiving standard-of-care medical therapy according to current guidelines, including: Dual antiplatelet therapy. Angiotensin-Converting Enzyme Inhibitors (ACE-i) or Angiotensin Receptor Blockers (ARBs). Statins. Beta-blockers. Exclusion Criteria: * Regular prior use of curcumin supplementation. * Hemodynamic instability or severe dyspnoea with clinical signs of congestion (elevated jugular venous pressure, pulmonary rales affecting \>1/3 of lung fields, hepatomegaly, ascites, or peripheral oedema). * History of prior myocardial infarction, previous percutaneous coronary intervention, or coronary artery bypass graft surgery. * Known hypersensitivity to curcumin or piperine. * Active malignancy. * Chronic infections (e.g., hepatitis, tuberculosis, or HIV). * Estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m² or rapidly declining renal function.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Curcuma xanthorrhiza are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Inflammation ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Curcuma xanthorrhiza Curcumin High sensitivity C-reactive protein HS-CRP Malondialdehyde ST-elevation myocardial infarction (stemi)

Contacts and locations

Locations

  • Universitas Diponegoro

    Semarang, Central Java, 50275, Indonesia

More trials for these conditions

Other studies related to the condition(s) this trial covers.